Form 4: Lineage Cell Therapeutics GC Vests RSUs

Lineage Cell Therapeutics' General Counsel, George A. Samuel III, acquired shares through RSU vesting and simultaneously disposed of shares for tax obligations.

Summary

• George A. Samuel III, General Counsel and Secretary of Lineage Cell Therapeutics, Inc. (LCTX), reported changes in his beneficial ownership.
• On February 11, 2026, Mr. Samuel acquired 6,075 common shares as a result of the vesting of a portion of Restricted Stock Units (RSUs).
• These RSUs were part of a grant of 24,303 RSUs made on February 11, 2022, which vested approximately 25% annually from 2023 to 2026.
• Concurrently, 2,502 common shares were disposed of by the issuer to satisfy statutory tax withholding requirements related to the RSU vesting.
• The shares disposed for tax purposes were valued at $1.8 per share.
• Following these transactions, Mr. Samuel directly beneficially owns 31,063 common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine insider transaction reflecting the vesting of previously granted equity, which aligns management's interests with shareholders. The tax-related disposition is a neutral, non-discretionary event.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the fulfillment of long-term incentive compensation for a key executive, aligning management's interests with shareholders.
• The acquisition of 6,075 common shares through RSU vesting increases the executive's direct stake in the company.

Negatives

• The disposition of 2,502 shares was solely for statutory tax withholding, which is a routine and non-discretionary event, not indicative of a negative outlook or a discretionary sale by the insider.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related dispositions are standard components of executive compensation packages across the biotechnology and pharmaceutical industries. This transaction reflects a pre-scheduled event rather than a discretionary investment decision.

Comparison to Industry Standards

• The structure of RSU grants with multi-year vesting schedules is a common practice in executive compensation, aligning with industry standards for long-term incentive plans.
• The disposition of shares solely for tax withholding is a standard, non-discretionary event, consistent with how equity compensation is handled across publicly traded companies globally.

Stakeholder Impact

• Shareholders: The vesting of RSUs for a key executive generally has a minor positive impact by reinforcing management's alignment with shareholder interests through equity ownership.

Key Dates

Recommendation

This Form 4 reports a standard RSU vesting and subsequent tax withholding, which is a pre-scheduled event and does not indicate a change in the company's fundamental outlook or the insider's confidence beyond the initial grant. Therefore, it does not warrant a change in investment recommendation.

Keywords

LCTX, Lineage Cell Therapeutics, Form 4, Insider Transaction, RSU Vesting, Executive Compensation, George A. Samuel III, Common Shares